New drug aims to keep lymphoma in check after CAR-T treatment
NCT ID NCT07622784
First seen Jun 18, 2026 · Last updated Jun 23, 2026 · Updated 1 time
Summary
This study tests whether the drug pirtobrutinib can help prevent relapse in people with B-cell lymphoma who have already received CAR-T cell therapy. Twenty adults will take pirtobrutinib daily for six months after their CAR-T infusion. The main goal is to see how many achieve a complete response at six months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun yat-sen university cancer center
Guangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pirtobrutinib
What this could lead to
If it works, this could offer a way to keep lymphoma from coming back after CAR-T therapy, potentially improving long-term control.
What could go wrong
This is a small, early-phase trial with only 20 people, so results may not apply widely. Pirtobrutinib may cause side effects or fail to improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.